Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of GEN3014 and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma and Other Blood Cancers

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying treatments for Relapsed or Refractory Multiple Myeloma and other blood-related cancers, known as hematologic malignancies. The study involves two treatments: GEN3014, also known as HexaBody®-CD38, and DARZALEX, which contains the active substance daratumumab. GEN3014 is a human monoclonal antibody, a type of protein designed to target specific cells, and is given as an infusion into a vein. DARZALEX is a solution for injection that is administered under the skin.

The purpose of this study is to evaluate the safety and tolerability of GEN3014 and to determine the appropriate dose for future studies. Participants will receive either GEN3014 or DARZALEX, and some may receive a placebo. The study will monitor participants for any side effects and how well the treatment is tolerated. The trial will also assess how the body processes GEN3014 and its effects on the disease.

Participants will be involved in the study for a period of time, during which they will receive regular check-ups and monitoring. The study aims to gather information that could help improve treatment options for people with these types of cancers. The trial is expected to continue until 2026, with the goal of finding effective and safe treatment options for patients with relapsed or refractory multiple myeloma and other hematologic malignancies.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will be required to sign an informed consent form. This is a document that confirms the patient's understanding and agreement to participate in the trial.

    The patient must provide fresh bone marrow samples for analysis. This is necessary to confirm eligibility and to gather baseline data.

  2. Step 2

    Initial assessment

    The patient will undergo a series of tests to ensure they meet the eligibility criteria. These tests include laboratory tests, an assessment of performance status, and a review of medical history.

    Women of reproductive potential must have a negative pregnancy test and agree to use effective contraception during the trial and for 12 months after the last dose of the study medication.

  3. Step 3

    Treatment phase

    The patient will receive the study medication, GEN3014 (HexaBody®-CD38), which is administered either subcutaneously or intravenously. The specific dosage and frequency will be determined based on the trial's phase and the patient's response.

    The treatment aims to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (MTD) of GEN3014. The patient's safety and the medication's tolerability will be closely monitored.

  4. Step 4

    Monitoring and follow-up

    Throughout the trial, the patient will be monitored for any side effects or adverse reactions. This includes regular check-ups, laboratory tests, and possibly electrocardiograms (ECGs).

    The patient's response to the treatment will be evaluated through various measures, such as objective response rate and progression-free survival.

  5. Step 5

    End of trial

    The trial is expected to conclude by March 2026. At the end of the trial, the patient will undergo a final assessment to evaluate the overall impact of the treatment.

    The patient will be informed about the results of the trial and any potential next steps regarding their treatment.

Who can join the trial?

17 criteria

  • Must be at least 18 years old.
  • Must sign an informed consent form before any screening procedures.
  • Must have fresh bone marrow samples collected during screening.
  • Must have an acceptable performance status, which is a measure of how well you can carry out daily activities.
  • Must have acceptable laboratory test results during the screening period.
  • For women who can have children, must agree to use effective birth control during the trial and for 12 months after the last dose of the study drug. This means using methods that are very reliable in preventing pregnancy.
  • For women who can have children, must have a negative pregnancy test at screening.
  • For women, must agree not to donate eggs for assisted reproduction during the trial and for 12 months after the last dose of the study drug.
  • For men who are sexually active with women who can have children and have not had a vasectomy, must agree to use a barrier method of birth control, like a condom, and must not donate sperm during the trial and for 12 months after the last dose of the study drug.
  • For patients with relapsed or refractory multiple myeloma (RRMM), must have documented multiple myeloma and show disease progression on the most recent treatment.
  • For patients with RRMM who have not received anti-CD38 antibody treatment, must have had at least 3 prior treatments, including specific types of drugs, or be resistant to these drugs.
  • For patients with RRMM who have received anti-CD38 antibody treatment, must have had at least 2 prior treatments and stopped certain medications for at least 4 weeks before the first dose of the study drug.
  • Must have specific levels of potassium and calcium in the blood.
  • For patients with relapsed or refractory acute myeloid leukemia (AML), must have failed all conventional therapy and not have a specific type of leukemia called acute promyelocytic leukemia (APL).
  • For patients with relapsed AML, must have had at least 2 prior therapies, except for a drug called hydroxyurea.
  • For patients with refractory AML, must have had at least 1 prior therapy, except for hydroxyurea.
  • Must have a life expectancy of at least 3 months at screening.

Who cannot join the trial?

3 criteria

  • Patients who have not been diagnosed with Relapsed or Refractory Multiple Myeloma or other blood-related cancers cannot participate. Relapsed means the cancer has returned after treatment, and Refractory means the cancer does not respond to treatment.
  • Patients who are not within the specified age range for the study cannot participate. The age range is not specified here, but it is important for eligibility.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

GEN3014 (HexaBody®-CD38) is a medication being studied for its potential to treat relapsed or refractory multiple myeloma and other blood-related cancers. This trial aims to find the right dose of GEN3014 that can be safely given to patients while also evaluating how well patients tolerate the medication. The study is designed to understand the effects of GEN3014 on these types of cancers and to determine the most effective and safe dosage for future treatments.

What is already known about the treatment

GEN3014 (HexaBody-CD38) – This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating relapsed or refractory multiple myeloma and other blood-related cancers. It is in the early phases of clinical research, with ongoing studies to determine its optimal dosage and safety profile. GEN3014 works by targeting a specific protein on the surface of cancer cells, helping the immune system to recognize and destroy these cells. It belongs to a class of drugs known as monoclonal antibodies, which are designed to specifically target and bind to certain proteins in the body.

Investigated diseases

  • Relapsed or Refractory Multiple Myeloma

    This is a type of blood cancer that affects plasma cells, which are a type of white blood cell found in the bone marrow. In relapsed or refractory cases, the disease has returned after treatment or does not respond to standard therapies. It typically progresses by causing damage to bones, kidneys, and the immune system. Patients may experience symptoms such as bone pain, fatigue, and frequent infections. The disease can lead to anemia and high levels of calcium in the blood. Over time, it can become more challenging to manage as it becomes resistant to treatments.

  • Other Hematologic Malignancies

    These are cancers that begin in the blood-forming tissue, such as the bone marrow, or in the cells of the immune system. They include various types of leukemia, lymphoma, and myelodysplastic syndromes. These malignancies often progress by disrupting the normal production and function of blood cells, leading to symptoms like fatigue, easy bruising, and increased risk of infections. As the disease advances, it can cause enlargement of the liver, spleen, or lymph nodes. The progression can vary significantly depending on the specific type of hematologic malignancy. They often require ongoing monitoring and management to address the changes in blood cell counts and related symptoms.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2023-507086-26-00Protocol codeGCT3014-01Estimated enrolment136 patientsSponsorGenmab A/S

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.